专注癌症药物研发的生物科技公司Revolution Medicines(RVMD.US)夜盘涨超13%,报121.5美元。消息面上,据英国《金融时报》引述知情人士称,默沙东正就收购Revolution Medicines进行磋商。报道称,交易作价或介乎280亿至320亿美元,若最终落实,将成为自2023年底辉瑞以430亿美元收购Seagen以来,规模最大的药业并购之一。此前艾伯维否认正在洽谈收购Revolution Medicines。
专注癌症药物研发的生物科技公司Revolution Medicines(RVMD.US)夜盘涨超13%,报121.5美元。消息面上,据英国《金融时报》引述知情人士称,默沙东正就收购Revolution Medicines进行磋商。报道称,交易作价或介乎280亿至320亿美元,若最终落实,将成为自2023年底辉瑞以430亿美元收购Seagen以来,规模最大的药业并购之一。此前艾伯维否认正在洽谈收购Revolution Medicines。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.